TP53 and cancer: These results also point to Gb3, rather than other similar GSLs, as being the particular elaborated GSL product of GlcCer that interacts with cSrc kinase and thereby directs cSrc‐signaling pathway forward towards preferential p53 mutant expression and consequent cancer drug resistance.